Celata is the first company leveraging transomics data and machine learning to see what others do not. We provide answers to crucial questions across drug discovery from target ID to patient selection. Our approach yields actionable and unbiased results based on data that meets three fundamental principles: (1) global, (2) dynamic, and (3) contextual.
Veramorph is developing a polymer-based pre-formed oral dosage technology as a more effective drug delivery vehicle for poorly soluble small molecule drugs. Our technology is capable of improving oral drug delivery performance of a much broader range of small molecule drugs the existing formulation methods. Our product, disintegrating polymer oral dosages (DPODs), can enable more effective drugs to be brought to clinical trials that will improve success rates and reduce the overall cost of successfully commercializing a drug product. Veramorph is developing an internal pipeline of reformulated products and is also seeking product development partnerships through licensing agreements with pharmaceutical companies.
Cache is a MIT startup from Prof. Mark Bathe’s lab seeking seed funding and entrepreneurs to help lead the next phase of customer discovery/hypothesis validation. Their technology enables massive and low-energy storage, up to millennium timescales, and random access of nucleic acid samples from a broad array of sources including viral, bacterial, mammalian, and synthetic for biological banking, molecular surveillance, ecological preservation, or massive archival data storage. They are seeking a passionate, adventurous, and creative entrepreneur to join their early-stage venture to help launch this technology into the 21st-century biotechnology space, and seed funding to catalyze the start-up. Their immediate aim is to recruit an entrepreneur who will be excited to mature their business plan using market discovery and research on product-market fit. They are ready to test the market’s appetite for this technology, developing partnerships along the way.